[1]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228-231，243.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
　WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(3):228-231，243.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
点击复制

提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年3期
页码:
228-231，243
栏目:
出版日期:
2021-03-25

文章信息/Info

Title:
To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy
作者:
王前程 刘伟涛 周忠江
(南方医科大学南方医院心血管内科,广东 广州 510515)
Author(s):
WANG Qiancheng;  LIU Weitao;  ZHOU Zhongjiang
(Department of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong ,China)
关键词:
甲状腺素转运蛋白; 淀粉样变; 心肌病; 诊断; 治疗
Keywords:
Transthyretin; Amyloidosis; Cardiomyopathy; Diagnosis; Treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2021.03.009
摘要:
甲状腺素转运蛋白淀粉样变性心肌病（ATTR-CM）是由于甲状腺素转运蛋白解离成单体后错误折叠为淀粉样物质，沉积于心肌间质而导致的一种心肌病。ATTR-CM主要分为突变型和野生型，临床表现无典型症状和体征。为提高国内在ATTR-CM的诊疗实践和临床研究，现简要介绍国内外关于ATTR-CM的最新诊断标准及治疗方法。
Abstract:
Transthyretin amyloid cardiomyopathy is caused by the wrong folding of transthyretin into amyloid substance after dissociation into monomer and deposition in myocardial interstitium. Transthyretin amyloid cardiomyopathy,which is no typical clinical symptoms and signs, is mainly divided into mutant type and wild type. In order to improve the diagnosis and treatment practice and clinical research of transthyretin amyloid cardiomyopathy in China, this paper briefly introduces the latest diagnostic criteria and treatment methods of transthyretin amyloid cardiomyopathy around the world.

参考文献/References:

[1].Maurer MS,Hanna M,Grogan M,et al. Genotype and phenotype of transthyretin cardiac amyloidosis:THAOS(Transthyretin Amyloid Outcome Survey)[J]. J Am Coll Cardiol,2016,68(2):161-172.
[2].Rowczenio DM,Noor I,Gillmore JD,et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations[J]. Hum Mutat,2014,35(9):E2403-E2412.
[3].Shin SC,Robinson-Papp J. Amyloid neuropathies [J]. Mt Sinai J Med,2012,79(6):733-748.
[4].Rapezzi C,Quarta CC,Obici L,et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype:an Italian perspective[J]. Eur Heart J,2013,34(7):520-528.
[5].Lane T,Fontana M,Martinez-Naharro A,et al. Natural history,quality of life,and outcome in cardiac transthyretin amyloidosis[J]. Circulation,2019,140(1):16-26.
[6].Connors LH,Sam F,Skinner M,et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin:a prospective,observational cohort study[J]. Circulation,2016,133(3):282-290.
[7].González-López E,Gallego-Delgado M,Guzzo-Merello G,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction[J]. Eur Heart J,2015,36(38):2585-2594.
[8].Ruberg FL,Maurer MS,Judge DP,et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy:the Transthyretin Amyloidosis Cardiac Study (TRACS)[J]. Am Heart J,2012,164(2):222-228.
[9].Ruberg FL,Berk JL. Transthyretin (TTR) cardiac amyloidosis [J]. Circulation,2012,126(10):1286-1300.
[10]. Patel KS ,Hawkins PN. Cardiac amyloidosis:where are we today? [J]. J Intern Med,2015 , 278(2):126- 144.
[11]. Givens RC,Russo C,Green P,et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center[J]. Aging Health,2013,9(2):229-235.
[12]. Quarta CC,Solomon SD ,Uraizee I,et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis[J]. Circulation,2014,129(18): 1840-1849.
[13]. Sanchis K,Cariou E ,Colombat M,et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis:clinical and echocardiographic features,impact on mortality[J]. Amyloid,2019,26(3):128-138.
[14]. Chacko L,Martone R ,Bandera F,et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis[J]. Eur Heart J,2020,41(14):1439-1447.
[15]. Gillmore JD,Maurer MS ,Falk RH,et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis[J]. Circulation,2016,133(24):2404-2412.
[16]. Gilbertson JA,Theis JD ,Vrana JA,et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue[J]. J Clin Pathol,2015,68(4):314-317.
[17]. Yamashita T,Ando Y ,Okamoto S,et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy[J]. Neurology,2012,78(9):637-643.
[18]. Benson MD . Liver transplantation and transthyretin amyloidosis [J]. Muscle Nerve,2013,47(2):157-162.
[19]. Carvalho A,Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis:issues and challenges [J]. Liver Transpl,2015,21(3):282-292.
[20]. Ericzon BG,Wilczek HE ,Larsson M,et al. Liver transplantation for hereditary transthyretin amyloidosis:after 20 years still the best therapeutic alternative?[J]. Transplantation,2015,99(9):1847-1854.
[21]. Nelson LM,Penninga L ,Sander K,et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy[J]. Clin Transplant,2013,27(2):203-209.
[22]. Maurer MS,Schwartz JH,Gundapaneni B,et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J].?N Engl J Med,2018,379(11):1007-1016.
[23]. Ikram A,Donnelly JP,Sperry BW,et al.?Diflunisal tolerability in transthyretin cardiac amyloidosis:a single center’s experience[J].?Amyloid,2018,25(3):197-202.
[24]. Judge DP,Heitner SB,Falk RH,et al.?Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy[J].?J Am Coll Cardiol,2019,74(3):285-295.
[25]. Minamisawa M,Claggett B,Adams D,et al.?Association of patisiran,an RNA interference therapeutic,with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis:the APOLLO study[J].?JAMA Cardiol,2019,4(5):466-472.
[26]. Benson MD,Waddington-Cruz M,Berk JL,et al.?Inotersen treatment for patients with hereditary transthyretin amyloidosis[J].?N Engl J Med,2018,379(1):22-31.
[27]. Benson MD,Dasgupta NR,Rissing SM,et al.?Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy[J].?Amyloid,2017,24(4):219-225.

更新日期/Last Update: 2021-05-27